Pharmacoepidemiology and Drug Safety· 2025Q1
A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
- 10citations
- Q1SCImago
- 2025year
Short summary
A pharmacovigilance study of 5,661 FDA Adverse Event Reporting System (FAERS) reports identified 105 adverse reaction signals for obeticholic acid (OCA), including 46 novel signals not previously listed on product labeling.
AI-generated from the title and abstract; the full text is not read.
Key points
- Analyzed 5,661 OCA-related adverse event reports from FDA FAERS (Q2 2016 - Q3 2023).
- Identified 105 adverse reaction signals for OCA using multiple detection methods.
- Discovered 46 new adverse reaction signals not previously mentioned in product labeling.
- Severe adverse events represented 25.53% of reports, with hospitalization being the most frequent outcome (18.41%).
- Top reported adverse events included pruritus, fatigue, and constipation.
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND AND OBJECTIVES: Based on the Adverse Event Reporting System (FAERS) data from the US FDA, this study mined the adverse drug reactions of obeticholic acid (OCA) in the real world and provided reference for clinical safe drug use. METHODS: Adverse event reports for OCA from the second quarter of 2016 to the third quarter of 2023 were extracted. The analysis for adverse reaction signal detection was conducted using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker methods. RESULTS: A total of 5661 OCA-related adverse event reports were collected, and 105 OCA-related adverse reaction signals were obtained, involving 14 systems, among which 46 new signals were not previously mentioned in the product labeling. Severe adverse event of OCA accounted for a relatively high proportion (1445 cases, 25.53%), among which the number of hospitalization reports was the largest (1042 cases, 18.41%). The top five adverse events were pruritus, fatigue, constipation, elevated blood alkaline phosphatase, and abdominal distention. The top five adverse reaction signals intensity were abnormal blood alkaline phosphatase, abnormal ratio of albumin globulin, spider nevus, combined with abnormal bilirubin, and γ-abnormal glutamyl transferase. DISCUSSION: Based on the pharmacovigilance study of the FAERS database, it is necessary to strengthen the clinical medication monitoring of OCA, so as to provide reference for effective pharmaceutical monitoring and rational clinical medication.
The authors' abstract, as published at the source. Pharmacoepidemiology and Drug Safety, 2025 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
ToxicologyPharmacology, Toxicology and Pharmaceutics